Based on our knowledge, this is the first randomized, double-blind, placebo-controlled, clinical trial investigating the effects of soy isoflavones on the serum levels of some hepatokines such as FGF-21 and fetuin A, as well as liver histological changes using Fibroscan in patients with NAFLD. The gene discussed is FGF21; the disease is metabolic dysfunction-associated steatotic liver disease.